TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26501831

Group type: EXPERIMENTAL
Intervention: Systemic magnesium infusion (initial loading dose 30 mg/kg over 15 minutes followed by continuous infusion 10 mg/kg/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Systemic magnesium infusion
Number of subjects: 60
Study: 24171961

Group type: EXPERIMENTAL
Intervention: Improved PAD (subcutaneous injection of bortezomib)
Number of subjects: 36

Group type: COMPARATOR
Intervention: PAD (conventional treatment)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Improved PAD
Number of subjects: 36

Group type: COMPARATOR
Intervention: PAD
Number of subjects: 36
Study: 20508979

Group type: EXPERIMENTAL
Intervention: Immediate treatment (IT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 40
Study: 18309943

Group type: EXPERIMENTAL
Intervention: Trimodality therapy (cisplatin 100 mg/m² and fluorouracil 1,000 mg/m²/d for 4 days on weeks 1 and 5 concurrent with radiation therapy 50.4 Gy total: 1.8 Gy/fraction over 5.6 weeks) followed by esophagectomy with node dissection
Number of subjects: 56

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 56
Study: 16845626

Group type: EXPERIMENTAL
Intervention: Diluted APSV (1:5 and 1:10)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Undiluted APSV
Number of subjects: 91
Study: 12702891

Group type: EXPERIMENTAL
Intervention: Mirtazapine 30‐45 mg/day
Number of subjects: 197

Group type: COMPARATOR
Intervention: Paroxetine 20‐30 mg/day
Number of subjects: 197
Study: 12848626

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (15-25 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral methotrexate with 5 mg folic acid (15-25 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Subcutaneous methotrexate (15-25 mg)
Number of subjects: 10
Study: 10589962

Group type: EXPERIMENTAL
Intervention: Triple therapy (MMF, CsA, and prednisone)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Discontinuation of CsA (group B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Continuation of triple therapy (group A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Discontinuation of prednisone (group C)
Number of subjects: 52
Study: 8704533

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 1872925

Group type: EXPERIMENTAL
Intervention: Fish oil dietary supplementation (10 g/day)
Number of subjects: 8
Study: 6343861

Group type: EXPERIMENTAL
Intervention: Acyclovir (1500 mg/m²/day for one week)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 3709648

Group type: EXPERIMENTAL
Intervention: MDL 72.222, 20 mg (slow i.v. injection)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31482354

Group type: EXPERIMENTAL
Intervention: VBLaST‐SS©
Number of subjects: 14

Group type: COMPARATOR
Intervention: FLS
Number of subjects: 14
Study: 29898677

Group type: EXPERIMENTAL
Intervention: Nurse-led case management intervention with targeted recommendations
Number of subjects: 127
Study: 29133336

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (IUD)
Number of subjects: 522
Study: 25445871

Group type: EXPERIMENTAL
Intervention: Capnography monitoring visible to staff
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard monitoring without capnography visibility (Control)
Number of subjects: 154
Study: 24259108

Group type: EXPERIMENTAL
Intervention: MAX‐ON setting (variable beam diameter)
Number of subjects: 12

Group type: COMPARATOR
Intervention: MAX‐OFF setting (4-mm-diameter spot)
Number of subjects: 12
Study: 21554269

Group type: EXPERIMENTAL
Intervention: Hyponatremia
Number of subjects: 1749

Group type: EXPERIMENTAL
Intervention: Plasma sodium
Number of subjects: 1749
Study: 18373843

Group type: EXPERIMENTAL
Intervention: GEM+X (gemcitabine-based combination chemotherapy)
Number of subjects: 4465

Group type: EXPERIMENTAL
Intervention: Platinum-based combinations (GEM+platinum)
Number of subjects: 4465

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine-based combinations (GEM+fluoropyrimidine)
Number of subjects: 4465

Group type: EXPERIMENTAL
Intervention: GEM+irinotecan, exatecan or pemetrexed
Number of subjects: 4465

Group type: EXPERIMENTAL
Intervention: GEM+X in patients with good performance status (PS)
Number of subjects: 4465

Group type: EXPERIMENTAL
Intervention: GEM+X in patients with poor performance status (PS)
Number of subjects: 4465
Study: 16931265

Group type: EXPERIMENTAL
Intervention: Anterior capsule polishing
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no anterior capsule polishing)
Number of subjects: 65
Study: 12608675

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional second-stage surgery
Number of subjects: 20
Study: 11279553

Group type: EXPERIMENTAL
Intervention: IDUs and crack cocaine smokers
Number of subjects: 216

Group type: COMPARATOR
Intervention: White men who have sex with both White and Alaska Native women
Number of subjects: 216
Study: 9091027

Group type: EXPERIMENTAL
Intervention: Doxazosin (1-16 mg, mean final dose 6.1 mg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nitrendipine (10-20 mg, mean final dose 15.6 mg)
Number of subjects: 61
Study: 8365297

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (2 g IV over 20 min followed by 2 g/h over 4 h)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate bolus (2 g over 20 min followed by placebo infusion)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (loading dose and infusion)
Number of subjects: 48
Study: 3632987

Group type: EXPERIMENTAL
Intervention: Social dramatics with videotape feedback
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 29082602

Group type: EXPERIMENTAL
Intervention: Thermotherapy (one session)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cryotherapy (every 2 to 3 weeks up to six sessions if required)
Number of subjects: 52
Study: 27301489

Group type: EXPERIMENTAL
Intervention: Organisational change intervention including smoke-free policy development, staff training, educational resources, and free nicotine replacement therapy.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual care provided by control services.
Number of subjects: 33
Study: 25187104

Group type: EXPERIMENTAL
Intervention: Glucose with 2.4 g · kg(‐1) · day(‐1) amino acids
Number of subjects: 132

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 132
Study: 23842110

Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis 35624
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 21169169

Group type: EXPERIMENTAL
Intervention: Online psycho-education program
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of noncompleters
Number of subjects: 370

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 370
Study: 18246696

Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg 4 times daily for adults; 20 to 40 mg/kg daily in 4 divided doses for children
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo (an emollient cream)
Number of subjects: 184
Study: 16540709

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia training (IHT) in hypoxia (FiO2 = 14.5%); 6 weeks duration; included two weekly high-intensity training sessions.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normoxia training (Nor group; FiO2 = 20.9%); 6 weeks duration; included two weekly high-intensity training sessions.
Number of subjects: 18
Study: 12733136

Group type: EXPERIMENTAL
Intervention: Mammographic screening (invitation to screening every 18 months)
Number of subjects: 51611
Study: 11533797

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study: 9412256

Group type: EXPERIMENTAL
Intervention: 0.4 g.kg-1 HBOC-201
Number of subjects: 12

Group type: COMPARATOR
Intervention: 3 ml.kg-1 6% HES 70,000/0.5
Number of subjects: 12
Study: 8241226

Group type: EXPERIMENTAL
Intervention: Cyclosporine target trough level reduced from 400-600 micrograms/L to 200-400 micrograms/L (Group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cyclosporine target trough level maintained at 400-600 micrograms/L (Group B)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 28
Study: 3888708

Group type: EXPERIMENTAL
Intervention: 0.1% domoprednate
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 0.03% domoprednate
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 0.1% hydrocortisone butyrate
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone valerate
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasole propionate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31119486

Group type: EXPERIMENTAL
Intervention: Surgical navigation (SN)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Non-surgical navigation (non-SN)
Number of subjects: 53
Study: 28116514

Group type: EXPERIMENTAL
Intervention: Compression CT (n=71)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard protocol CT (n=97)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Compression CT
Number of subjects: 168
Study: 25981560

Group type: EXPERIMENTAL
Intervention: -318 C/T genotype in acute rejection group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: T allele at -318 position
Number of subjects: 34
Study: 22537207

Group type: EXPERIMENTAL
Intervention: Once-daily (q.d.) pramipexole
Number of subjects: 590

Group type: COMPARATOR
Intervention: Three-times-daily (t.i.d.) pramipexole
Number of subjects: 590
Study: 21314643

Group type: EXPERIMENTAL
Intervention: E (high-intensity physical resistance strength training and walking)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: SA (individualized social activity)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: ESA (E and SA combined)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 165
Study: 19190632

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg m(‐2), d1, d8, 100‐min infusion) and Oxaliplatin (100 mg m(‐2), d1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gemcitabine and Oxaliplatin combination
Number of subjects: 50
Study: 16440332

Group type: EXPERIMENTAL
Intervention: 50 U Botox in each parotid gland
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12548062

Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Prednisone (40 mg)
Number of subjects: 33
Study: 11079654

Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no troglitazone)
Number of subjects: 52
Study: 9366100

Group type: EXPERIMENTAL
Intervention: Piretanide 6 mg (PIR)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg (HCT)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Altizide 15 mg - Spironolactone 25 mg (ALT-SP)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: All drugs (PIR, HCT, ALT-SP)
Number of subjects: 800
Study: 1608733

Group type: EXPERIMENTAL
Intervention: subliminal presentation of memory-improvement affirmations embedded in relaxing music
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: supraliminal presentation of relaxing music
Number of subjects: 60

Group type: COMPARATOR
Intervention: no sound
Number of subjects: 60
Study: 3910541

Group type: EXPERIMENTAL
Intervention: Rosoxacin 150 mg twice daily for 10 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Triple tetracycline (Deteclo) 300 mg twice daily for 10 days
Number of subjects: 62
Study: 31880078

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (8 weeks, one home visit and seven once-weekly telephone calls)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard care (weekly social telephone calls)
Number of subjects: 58
Study: 29521312

Group type: EXPERIMENTAL
Intervention: Surface ECG-guided LV lead placement
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard unguided CRT
Number of subjects: 80
Study: 27716298

Group type: EXPERIMENTAL
Intervention: Collaborative Assessment and Management of Suicidality (CAMS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CAMS and TAU
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CAMS
Number of subjects: 100
Study: 24673575

Group type: EXPERIMENTAL
Intervention: Black tea extract (BTE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22801416

Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin
Number of subjects: 116

Group type: COMPARATOR
Intervention: 40 mg simvastatin/10 mg ezetimibe
Number of subjects: 116
Study: 20026503

Group type: COMPARATOR
Intervention: Marlboro snus (MSNUS) with >50% reduction in cigarette consumption (DU group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Marlboro snus (MSNUS) with complete cessation of cigarette smoking (SN group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Control group (CS) continuing to smoke their own brand
Number of subjects: 120

Group type: COMPARATOR
Intervention: No tobacco products (NT group)
Number of subjects: 120
Study: 19209795

Group type: EXPERIMENTAL
Intervention: Protective endotracheal intubation (Group II)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Classical endotracheal intubation (Group I)
Number of subjects: 90
Study: 15899726

Group type: EXPERIMENTAL
Intervention: Metabolife Ephedra Free (half the normal recommended dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12789955

Group type: EXPERIMENTAL
Intervention: Oral‐B Stages toothbrushes
Number of subjects: 0
Study: 9583761

Group type: EXPERIMENTAL
Intervention: Levodopa (100 mg) plus benserazide (25 mg) taken three times per day for 28 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 25
Study: 9450173

Group type: EXPERIMENTAL
Intervention: Tablet (treatment A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Capsule (treatment B, Gramidil)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 12
Study: 1929132

Group type: EXPERIMENTAL
Intervention: Wound compression pads
Number of subjects: 120
Study: 7145542

Group type: EXPERIMENTAL
Intervention: Presence of one or more abnormal features in parent or child
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Unkempt children
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Children with abnormal bruises, burns, or bites
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Presence of unkempt condition and abnormal parenting pattern
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Unkempt child with abnormal parenting pattern
Number of subjects: 476
Study: 31965170

Group type: EXPERIMENTAL
Intervention: Sectioning of the periareolar dermis in the experimental group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no sectioning of the periareolar dermis)
Number of subjects: 41
Study: 29791252

Group type: EXPERIMENTAL
Intervention: Gait Modification Group (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control Group (n = 8)
Number of subjects: 16
Study: 29339913

Group type: EXPERIMENTAL
Intervention: 12-week anti-inflammatory diet program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 24166562

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A-tDCS) 1 mA for 10 min, n = 18
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham stimulation 1 mA for 25 s, n = 19
Number of subjects: 37
Study: 21771770

Group type: EXPERIMENTAL
Intervention: IVIG 0.5‐1.0 g/kg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (saline equivalent volume)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: IVIG 0.5 g/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: IVIG 1.0 g/kg
Number of subjects: 35
Study: 19416445

Group type: EXPERIMENTAL
Intervention: Placement of rubber dam
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Placement of matrix band and wedge
Number of subjects: 205

Group type: COMPARATOR
Intervention: Baseline (before any dental treatment)
Number of subjects: 205
Study: 17450065

Group type: EXPERIMENTAL
Intervention: Chair with a flat seat pan plus miscellaneous items
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Chair with a curved seat pan plus miscellaneous items
Number of subjects: 277

Group type: COMPARATOR
Intervention: Miscellaneous items (control group)
Number of subjects: 277
Study: 15476910

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Enalapril (5 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 80
Study: 9413770

Group type: EXPERIMENTAL
Intervention: Metabolic acidosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correction of metabolic acidosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy children (Control)
Number of subjects: 0
Study: 8498314

Group type: EXPERIMENTAL
Intervention: Amlodipine 1.25 mg daily
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg daily
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Amlodipine 5.0 mg daily
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Amlodipine 10.0 mg daily
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Amlodipine (all doses > 1.25 mg)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 210
Study: 3549810

Group type: EXPERIMENTAL
Intervention: 3% topical minoxidil applied twice daily for 64 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 12 weeks, then 3% topical minoxidil for 52 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuation of 3% topical minoxidil for a second year
Number of subjects: 30
Study: 29849840

Group type: EXPERIMENTAL
Intervention: Exercise training combined with increased physical activity (n=38)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Exercise training alone (n=38)
Number of subjects: 76
Study: 26559015

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg.kg(‐1))
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (6% hydroxyethyl starch)
Number of subjects: 55
Study: 24566571

Group type: EXPERIMENTAL
Intervention: Capilen® cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 30
Study: 22726566

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied to one leg once a day for 14 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (non-stimulated leg)
Number of subjects: 11
Study: 20408017

Group type: EXPERIMENTAL
Intervention: Liquid carbon dioxide cooling shirt (CC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No cooling (NC)
Number of subjects: 10
Study: 18758393

Group type: EXPERIMENTAL
Intervention: Antiretroviral drugs (lamivudine, stavudine, zidovudine, nevirapine, nelfinavir, ritonavir, lopinavir) measured in breast milk using a novel extraction method and high-performance liquid chromatography-tandem mass spectrometry.
Number of subjects: 0
Study: 16126716

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pacing
Number of subjects: 10
Study: 12716814

Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 2283

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2283
Study: 10500060

Group type: EXPERIMENTAL
Intervention: Norfloxacin (800 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid (1500 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8924134

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 113

Group type: COMPARATOR
Intervention: Non-steroid treatment (Control)
Number of subjects: 113
Study: 1986897

Group type: EXPERIMENTAL
Intervention: Nitroprusside administered using Abbott infusion pump
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nitroprusside administered using IMED infusion pump
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nitroprusside administered using 3M/AVI infusion pump
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nitroprusside administered using IVAC infusion pump
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nitroprusside administered using Kendall McGaw infusion pump
Number of subjects: 6
Study: 6340183

Group type: EXPERIMENTAL
Intervention: Carprofen, 300 mg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Indomethacin, 75 mg/day
Number of subjects: 28
Study: 30803046

Group type: EXPERIMENTAL
Intervention: Antireflux metal stent (ARMS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Covered self‐expandable metal stents (SEMS)
Number of subjects: 104
Study: 29087809

Group type: EXPERIMENTAL
Intervention: Structured postoperative physiotherapy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Structured postoperative physiotherapy (attended at least 50% of sessions)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard postoperative approach
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Both groups (structured physiotherapy and standard approach)
Number of subjects: 201
Study: 27484710

Group type: EXPERIMENTAL
Intervention: Multipurpose solutions (MPS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Different MPS
Number of subjects: 30
Study: 25103686

Group type: EXPERIMENTAL
Intervention: e‐Exercise (12-week intervention with maximum five face‐to‐face physical therapy contacts and a web‐based program)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (physical therapy)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: e‐Exercise
Number of subjects: 200
Study: 21926097

Group type: EXPERIMENTAL
Intervention: Room Air (RA) foam sclerotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbon Dioxide (CO(2)) foam sclerotherapy
Number of subjects: 20